How should Efudix (5‑fluorouracil 5% cream) be used, dosed, and what precautions are needed for adult patients with actinic keratoses or superficial basal cell carcinoma and intact skin?

Efudix (5-Fluorouracil 5% Cream) for Actinic Keratoses and Superficial Basal Cell Carcinoma

Direct Answer

For actinic keratoses, apply Efudix 5% cream twice daily for 2-4 weeks to the affected field (maximum 500 cm²), and for superficial basal cell carcinoma, apply twice daily for up to 12 weeks when surgery is impractical. 1

---

Indications and Patient Selection

Actinic Keratoses

• Efudix is FDA-approved and strongly recommended for multiple actinic keratoses as field-directed therapy 2, 1
• Reserve for patients with multiple or confluent lesions rather than isolated lesions (where cryosurgery is preferred) 2
• Particularly effective for face and scalp lesions, achieving 38-70% complete clearance rates 3, 4

Superficial Basal Cell Carcinoma

• Use only when conventional surgery is impractical (multiple lesions, difficult treatment sites, or when surgery is contraindicated) 2, 1
• Histologic diagnosis must be established before treatment 1
• Achieves approximately 90-93% cure rate for superficial BCC 1, 5
• Surgery remains preferred for isolated, easily accessible lesions with nearly 100% success rates 2, 1

---

Dosing Regimens

Standard Daily Dosing (Most Effective)

• Apply twice daily for 2-4 weeks for actinic keratoses 2, 3, 6
• Apply twice daily for up to 12 weeks for superficial basal cell carcinoma 1, 5
• Treatment can be stopped sooner if lesions clinically resolve 5
• Maximum treatment area: 500 cm² per course due to systemic toxicity concerns 3, 4

Alternative Weekly Pulse Dosing (Better Tolerated, Less Effective)

• Apply twice daily for 1 day per week for 12 weeks 7
• This regimen is significantly less effective than daily dosing (median lesion count 3 vs 0 at 52 weeks, p<0.05) but causes less inflammation 7
• Consider only for patients who cannot tolerate daily application 8

---

Application Technique and Precautions

Proper Application

• Apply a thin layer to the entire affected field, not just visible lesions 3
• Systemic absorption is approximately 5-6% of applied dose when used on face and neck 1
• Wash hands thoroughly after application 3

Critical Contraindications and Warnings

• Avoid application near eyes; use extreme caution in periorbital area 3
• Contraindicated on lower legs and other poor-healing sites due to ulceration risk 3
• Exercise caution in patients with dihydropyrimidine dehydrogenase (DPD) deficiency 3
• Not appropriate for genetic conditions predisposing to skin cancer (basal cell nevus syndrome, xeroderma pigmentosum) or connective tissue diseases (lupus, scleroderma) 2

---

Expected Side Effects and Management

Common Local Reactions (>90% of Patients)

• Expect soreness, erythema, crusting, and erosions—these are necessary for therapeutic effect 3, 4, 7
• Inflammation correlates with efficacy: mean inflammation score of 3.8 in patients who cleared vs 1.9 in those who did not (p<0.05) 7
• Local reactions include skin irritation, ulceration, pruritus, and eczematous reactions 9

Patient Counseling Strategy

• Counsel extensively before initiation about expected inflammatory reactions 3, 4
• Start with a small test area to establish tolerance before treating entire field 4
• Permit flexible dosing schedules or treatment breaks to maintain adherence 3
• Patients may wash the area and apply thin emollient during treatment 3
• If reaction is excessive, apply weak topical steroid (hydrocortisone 1%) 3

---

Enhanced Efficacy: Combination with Calcipotriene

Superior Outcomes with Combination Therapy

• 5-fluorouracil 5% combined with calcipotriene 0.005% ointment achieves 87.8% mean reduction in AK count versus 26.3% with 5-FU alone 4
• Apply once daily for 4 consecutive days to affected field 3
• This abbreviated regimen maintains efficacy while dramatically reducing treatment duration 3
• Maximum treatment area remains 500 cm² 3

---

Monitoring and Follow-Up

Treatment Response Assessment

• Evaluate response 4-8 weeks after completing treatment course 3
• For superficial BCC, excise lesional site 3 weeks after treatment completion for histologic confirmation of cure 5
• Biopsy any persistent thick or suspicious lesions to rule out invasive carcinoma 3

Long-Term Outcomes

• Single course effectively reduces AK counts for longer than 2 years 10
• Recurrence rates approach 50% within first year, necessitating ongoing monitoring 4
• Complete clearance at 6 months: 38% (maintained through 52 weeks in responders) 10
• Fluorouracil group required first spot treatment at 6.2 months vs 6.0 months for controls (HR 0.69, p<0.001) 10

---

Comparative Effectiveness

Versus Other Topical Agents

• 5-FU 5% is more effective than imiquimod 5% for reducing final AK count (94% vs 66% reduction, p<0.05) and achieving complete clearance (84% vs 24%, p<0.01) 6
• 5-FU achieves clearance more rapidly than imiquimod 6
• 5-FU demonstrates similar efficacy to imiquimod for superficial BCC with comparable safety and cosmetic outcomes 2

Versus Cryosurgery

• Cryosurgery is preferred for isolated lesions (75% complete response) 3
• 5-FU is superior for field treatment of multiple lesions 2

---

Critical Clinical Pitfalls

Common Errors to Avoid

• Do not use for nodular or infiltrative BCC—only superficial subtypes 2
• Do not treat areas larger than 500 cm² in a single course 3, 4
• Do not discontinue prematurely due to inflammation—this indicates therapeutic activity 7
• Do not use on lower extremities or other poor-healing sites 3

When to Choose Alternative Therapy

• Surgery remains gold standard for isolated, accessible BCC 2, 1
• Consider cryosurgery for few isolated AKs 2, 3
• Reserve 5-FU for field treatment when surgery/radiation is contraindicated or impractical 2

---

Mandatory Concurrent Intervention

All patients must use high-SPF sunscreen applied twice daily and practice strict UV protection to prevent new lesion development 2, 3, 4